RAPA-201 Therapy of Solid Tumors

NCT05144698 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Small Cell and Non-small Cell Lung Cancer
Head and Neck Cancer
Squamous Cell Carcinoma of Oral Cavity
Squamous Cell Carcinoma of Larynx
Squamous Cell Carcinoma of Nasopharynx
Squamous Cell Carcinoma of Other Specified Sites of Skin
Malignant Melanoma
Esophageal Squamous Cell Carcinoma

Interventions

BIOLOGICAL: RAPA-201 Rapamycin Resistant T Cells
DRUG: Chemotherapy Prior to RAPA-201 Therapy
DRUG: Pembrolizumab (PD-1 Blocking Antibody)

Sponsor

Rapa Therapeutics LLC